[Use of protamine sulfate, epsilon-aminocaproic acid and serotonin in experimental hypofibrinogenemia and fibrinolysis caused by stimulation of the anticoagulant system].
D000347:Afibrinogenemia / Q000188:drug therapy* / Q000209:etiology; D000614:Aminocaproates / Q000627:therapeutic use*; D015119:Aminocaproic Acid / Q000627:therapeutic use*; D000818:Animals; D001285:Atropine; D001778:Blood Coagulation Disorders / Q000188:drug therapy / Q000209:etiology; D004338:Drug Combinations; D004837:Epinephrine / Q000008:administration & dosage; D005260:Female; D005340:Fibrinogen / Q000008:administration & dosage; D005341:Fibrinolysin / Q000008:administration & dosage; D005342:Fibrinolysis; D006493:Heparin / Q000008:administration & dosage; D010958:Plasminogen / Q000008:administration & dosage; D011479:Protamines / Q000627:therapeutic use*; D051381:Rats; D012701:Serotonin / Q000008:administration & dosage / Q000627:therapeutic use*; D013917:Thrombin
D000614:Aminocaproates; D004338:Drug Combinations; D011479:Protamines; D012701:Serotonin; D001285:Atropine; D005340:Fibrinogen; D010958:Plasminogen; D006493:Heparin; D013917:Thrombin; D005341:Fibrinolysin; D015119:Aminocaproic Acid; D004837:Epinephrine
Ispol'zovanie protaminsul'fata, épsilon-aminokapronovoĭ kisloty i serotonina pri éksperimental'noĭ gipofibrinogenemii i fibrinolize, obuslovlennykh vozbuzhdeniem protivosvertyvaiushcheĭ sistemy